Don Dizon, FACP, FASCO, MD, Brown University, Providence, RI, provides an overview of current antibody-drug conjugates (ADCs) indicated for gynecologic cancers. Mirvetuximab soravtansine is a novel ADC for patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer, and tisotumab vedotin is an ADC for patients with recurrent or metastatic cervical cancer. Prof. Dizon additionally highlights the need for additional ophthalmological care for patients receiving these ADCs due to atypical toxicities. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
